Ross v. Blue Care Network of Mich.

722 N.W.2d 223, 271 Mich. App. 358
CourtMichigan Court of Appeals
DecidedOctober 2, 2006
DocketDocket 266240
StatusPublished
Cited by3 cases

This text of 722 N.W.2d 223 (Ross v. Blue Care Network of Mich.) is published on Counsel Stack Legal Research, covering Michigan Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ross v. Blue Care Network of Mich., 722 N.W.2d 223, 271 Mich. App. 358 (Mich. Ct. App. 2006).

Opinion

PER CURIAM.

Respondent appeals by leave granted the trial court’s order that reversed in part the Office of Financial and Insurance Service (OFIS) Commissioner’s decision to deny petitioner’s claim for emergency medical coverage. We affirm in part and reverse in part and remand.

I. FACTS

In this medical insurance case, we review the OFIS Commissioner’s determination that respondent prop *360 erly denied most of the benefits sought because petitioner’s late husband Douglas Ross’s initial treatment was not “emergency care” and because Ross’s follow-up care was not medically necessary to stabilize his condition.

Douglas Ross, who was insured by Blue Care Network of Michigan (BCN), a health maintenance organization, began complaining in February 2002 of back pain, for which he received pain medication and a referral to physical therapy. By April 2002, Ross could not walk or stand from the intense pain. Doctors then determined that he had multiple myeloma, a spine tumor, fractured lumbar vertebrae, and spinal stenosis. He began chemotherapy. He also underwent decompression laminectomy surgery to relieve the pressure on his spine.

In late May 2002, Ross was seen at the University of Michigan to be considered for a bone marrow transplant; it was determined that he would be reevaluated after his fourth round of chemotherapy. Although Ross continued chemotherapy, by June 24, 2002, he had developed additional nodules and lesions in the left shoulder, right side, and right eye and had gained 22 pounds in two weeks. Doctors determined that he had a very aggressive and virulent strain of multiple myeloma that was resistant to the type of chemotherapy he had been receiving.

According to petitioner Desiree Ross, Dr. Ronald Lutsic, Ross’s radiological oncologist, indicated on June 25, 2002, that Ross was no longer a candidate for a bone marrow transplant given that the myeloma had spread to his soft tissues. Dr. Lutsic allegedly said that he had never before seen myeloma as aggressive. He advised radiation to ease the pain. According to petitioner, Lutsic indicated that he would pursue treatment in *361 Arkansas if he were Ross. No other change in Ross’s primary treatment plan was recommended.

Given Lutsic’s failure to prescribe anything other than radiation, on June 26, 2002, petitioner contacted Matt Rhodes, RN, at the University of Arkansas, who advised that Ross likely had extra medullary multiple myeloma, a rare type. Rhodes stated that the condition was treatable, but time was of the essence. That day, petitioner asked Dr. William Silverstone, Ross’s primary care physician, for a referral to the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences (UAMS), an out-of-network provider. 1 UAMS treats more cases of multiple myeloma than any other treatment center in the world. BCN advised Silverstone that the referral would take ten to 14 days because BCN needed to review the proposed treatment plan. Rhodes then indicated to BCN that Ross would need to be examined before UAMS could provide a proposed treatment plan.

On July 2, 2002, Ross began to be evaluated at UAMS. On July 8, 2002, Dr. Frits VanRhee admitted Ross to the UAMS hospital, noting that Ross had “very aggressive” multiple myeloma that required intensive therapy. Dr. VanRhee indicated that at that time, Ross was in “terrible shape” and was one week away from death. While Ross was hospitalized, he developed a staph infection, which was treated. He also received a different type of chemotherapy, called “DT-PACE,” which resolved some of the nodules and lesions, the swelling in his right eye, and the fluid retention in his legs. He was discharged on July 23, 2002. He was *362 readmitted on August 1-2, 2002, but the treatment he received during that admission is unclear.

On August 16, 2002, Dr. VanRhee wrote that Ross “clearly will need further therapy.” Dr. VanRhee admitted Ross to the hospital again and started another round of DT-PACE chemotherapy because the myeloma was recurring. The plan was to have Ross receive a bone marrow transplant from his brother. One of Ross’s treating physicians in Michigan, Stephen Goldfarb, an oncologist, concurred on August 30,2002, that Ross had a very poor prognosis and that the only treatment of any known value was a bone marrow transplant.

On September 24, 2002, Dr. VanRhee noted that Ross’s myeloma was in remission and he was scheduled for a bone marrow transplant. Dr. VanRhee also observed that “this patient essentially had been given up on at the University of Michigan ....” He added, in the university’s defense, “most physicians and oncologists never see such aggressive myeloma and have little experience in dealing with this highly aggressive explosive form of tissue-based myelomatous disease.” Dr. VanRhee noted that Ross required extremely specialized care in a center totally dedicated to myeloma — only one or two of which exist in the United States. Dr. Goldfarb agreed that Ross’s best treatment would be the tandem bone marrow transplant from UAMS given the very aggressive nature of his myeloma. Ross received a bone marrow transplant at UAMS; however, he died on April 6, 2003.

BCN denied coverage for the treatments Ross received at UAMS between June 30, 2002, and November 17, 2002. Ross, however, also was hospitalized from December 23, 2002, through March 3, 2003. For an unknown reason, BCN apparently has bifurcated the treatment Ross received and has only addressed his *363 treatment up until November 17, 2002. Although BCN paid UAMS for some of the services rendered, apparently BCN has received reimbursement from UAMS for those payments.

In December 2002, petitioner filed a “step one member grievance” to challenge BCN’s failure to cover the services from UAMS. In January 2003, the BCN associate medical director issued a decision that Ross was required to use in-network resources and denied his request for reimbursement. Petitioner then filed a “step two member grievance,” which was denied because Ross had “self-referred” to UAMS despite the fact that his primary care physician allegedly had referred him to the University of Michigan. 2

In April 2003, petitioner requested an external review by the Commissioner of the Office of Financial and Insurance Services (Commissioner) under the Patient’s Right to Independent Review Act (PRIRA), MCL 550.1901 et seq. Pursuant to MCL 550.1917, the Commissioner assigned the case to an independent review organization (IRO), Permedion, which arranged for Ross’s records to be reviewed by a practicing physician who was board-certified in internal medicine, medical oncology, and hematology.

The IRO submitted the initial review on May 16, 2003. The IRO determined that Ross’s care was emergency treatment, as both Ross and Dr. VanRhee opined that time was of the essence where Ross had not responded to chemotherapy.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Ross v. Blue Care Network of Michigan
747 N.W.2d 828 (Michigan Supreme Court, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
722 N.W.2d 223, 271 Mich. App. 358, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ross-v-blue-care-network-of-mich-michctapp-2006.